Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.2K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.7K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

106
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
106

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia-Related.

Cancer reports (Hoboken, N.J.)·2026
Same author

Dopamine inhibits retinal pathological neovascularization in the oxygen-induced retinopathy mouse model.

The Journal of pathology·2026
Same author

Machine learning identifies a NETs-related four-gene diagnostic signature for abdominal aortic aneurysm.

Medicine·2026
Same author

CreER activation transiently disrupts angiogenesis by reducing proliferation and promoting apoptosis in vascular endothelial cells.

Angiogenesis·2026
Same author

Performance and additional benefits of MALDI-TOF-MS in M-protein detection in plasma cell disorders.

Annals of medicine·2026
Same author

Genetic variations in three insecticide targets in the disease vector <i>Culex quinquefasciatus</i> from Mianyang, China: simultaneous detection of novel mutations RDL A296G and VGSC A1007T.

Frontiers in cellular and infection microbiology·2026

Related Experiment Video

Updated: Dec 1, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Emerging agents and regimens for multiple myeloma.

Yang Yang1, Yi Li1, Huiyao Gu1

  • 1Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Journal of Hematology & Oncology
|November 10, 2020
PubMed
Summary

Treatments for multiple myeloma (MM) have advanced, but relapsed and refractory MM (RRMM) still presents challenges. This review highlights novel agents and regimens in clinical development for RRMM.

Keywords:
BiTECAR-TCheckpoint inhibitorImmunotherapyMonoclonal antibodyMultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Related Experiment Videos

Last Updated: Dec 1, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) outcomes have improved with proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb), and stem cell transplantation.
  • Relapsed and refractory multiple myeloma (RRMM) remains a significant clinical challenge despite advances in treatment.

Purpose of the Study:

  • To review the latest clinical developments of novel agents and regimens for treating relapsed and refractory multiple myeloma (RRMM).

Main Methods:

  • Literature review of recent clinical trials and studies on novel therapeutic agents for multiple myeloma.
  • Summary of emerging drug classes including new proteasome inhibitors, monoclonal antibodies, epigenetic agents, and cytokines.
  • Overview of novel therapeutic strategies such as XPO-1 inhibitors, BCMA-targeted therapies, antibody-drug conjugates, and CAR-T cells.

Main Results:

  • Several novel agents including ixazomib, marizomib, oprozomib, isatuximab, MOR202, ricolinostat, siltuximab, and selinexor are in active clinical development.
  • Selinexor, the first XPO-1 inhibitor, has been approved for RRMM.
  • BCMA-targeted therapies, antibody-drug conjugates, and CAR-T cells show significant potential to revolutionize RRMM treatment.

Conclusions:

  • The landscape of multiple myeloma treatment is evolving with the introduction of novel therapies.
  • Continued research and clinical development of these agents offer new hope for patients with relapsed and refractory multiple myeloma.
  • Emerging therapies hold promise for significantly improving outcomes in challenging RRMM cases.